Now is the time for new manufacturing sites to adopt and implement new technologies; to transform pharma manufacturing from being reliant on historical operational methods and facilitate the ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...